MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: Disitamab Vedotin

Disitamab Vedotin

Latest news

Tag

Clinical Updates

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patie

Oct 15, 2026
news

Disitamab Vedotin Plus Gemcitabine Shows Promise as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.

Dec 17, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story